Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 11.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 167,355 shares of the company's stock after selling 22,250 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.34% of Amphastar Pharmaceuticals worth $8,122,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after acquiring an additional 273 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company's stock worth $452,000 after purchasing an additional 275 shares in the last quarter. Blue Trust Inc. raised its holdings in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares in the last quarter. nVerses Capital LLC raised its holdings in Amphastar Pharmaceuticals by 18.2% in the third quarter. nVerses Capital LLC now owns 2,600 shares of the company's stock worth $126,000 after purchasing an additional 400 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Amphastar Pharmaceuticals by 3.9% in the second quarter. Arizona State Retirement System now owns 10,943 shares of the company's stock worth $438,000 after purchasing an additional 410 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the transaction, the director now owns 33,971 shares in the company, valued at $1,463,130.97. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO William J. Peters sold 10,282 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company's stock, valued at approximately $4,162,175.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 17,101 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the transaction, the director now directly owns 33,971 shares of the company's stock, valued at approximately $1,463,130.97. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,383 shares of company stock worth $1,524,123. Corporate insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH traded down $0.26 during trading hours on Tuesday, reaching $51.15. The stock had a trading volume of 155,843 shares, compared to its average volume of 393,838. The stock has a fifty day moving average of $47.99 and a 200 day moving average of $43.59. The stock has a market cap of $2.50 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, October 18th. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.